...
首页> 外文期刊>Bone marrow transplantation >Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
【24h】

Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.

机译:异基因TBI与异基因干细胞移植后血液恶性肿瘤患者的T细胞混合嵌合体较少,但与busulphan相比,复发风险增加。

获取原文
获取原文并翻译 | 示例
           

摘要

We prospectively evaluated mixed chimerism (MC) in the T cell and myeloid lineages and its correlation to busulphan, single-dose total body irradiation (TBI) and fractionated TBI (fTBI) conditioning in 180 patients with haematological malignancies after allogeneic stem cell transplantation (SCT). In all patients receiving busulphan, the area under curve (AUC) was calculated. The incidence of MC in the T cell lineage was significantly lower in patients receiving fTBI (22%) compared to those given TBI (53%, P=0.02) or busulphan (47%, P<0.01). The incidence of myeloid MC did not differ between the three groups. The overall probability of acute graft-versus-host disease grades II-IV was significantly higher in patients with complete T cell donor chimerism (49%) compared to patients with T cell MC (23%, P<0.001). The incidence of T cell and myeloid MC after SCT did not differ between low (55%), medium (42%) and high (43%) AUC levels of busulphan during conditioning. Patients receiving fTBI had a significantly higher probability of relapse compared to busulphan-treated patients (44 vs l6%, P=0.01). In multivariate analysis adjusted for diagnosis, busulphan-treated patients showed both a better survival (P=0.04) and less probability of relapse (0.03) compared to TBI-treated patients.
机译:我们前瞻性评估了异基因干细胞移植(SCT)后180例血液系统恶性肿瘤患者中T细胞和髓系的混合嵌合(MC)及其与busulphan,单剂量全身照射(TBI)和分级TBI(fTBI)调节的相关性)。在所有接受busulphan治疗的患者中,计算曲线下面积(AUC)。与接受TBI(53%,P = 0.02)或Busulphan(47%,P <0.01)的患者相比,接受fTBI的患者(22%)在T细胞谱系中MC的发生率显着降低。骨髓MC的发生率在三组之间没有差异。完全T细胞供体嵌合的患者(49%)与T细胞MC患者(23%,P <0.001)相比,急性移植物抗宿主疾病II-IV级的总体可能性显着更高。 SCT后T细胞和髓样MC的发生率在调理过程中,在肉豆蔻的低(55%),中(42%)和高(43%)AUC水平之间没有差异。接受fTBI治疗的患者复发率明显高于接受布柳芬治疗的患者(44 vs 16%,P = 0.01)。在针对诊断进行了调整的多变量分析中,相比于TBI治疗的患者,接受布洛芬治疗的患者显示出更好的生存率(P = 0.04)和更低的复发率(0.03)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号